The U.S. has approved long-acting injectable PrEP options such as cabotegravir (Apretude) and lenacapavir (Yzugo), yet major challenges remain around equitable access, demand generation, and health-system readiness. This project explores what the United States can learn from low- and middle-income countries (LMICs) that successfully expanded injectable contraceptives, an intervention with striking parallels to injectable PrEP.